The discovery of this mechanism also provides scientific direction for the development of therapeutic drugs; the characteristics of the viral S protein’s binding to human ACE2 indicate that selective disruption of this binding can intervene in viral infection, including the use of S protein antibodies to neutralize the virus, soluble ACE2 fragments to occupy binding sites, and protease inhibitors targeting the S protein cleavage sites [26,27,28,29]. This evidence concerns the gene PROS1 and viral infectious disease.